| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.17 | 9e-05 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0004 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.18 | 0.0006 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0006 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |